Medical Students Articles

Med Student

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Kaira K et al. – Amrubicin is an active and well–tolerated regimen in patients with previously treated lung cancer. Amrubicin 35mg/m2 seems to achieve similar efficacy with less toxicity than amrubicin 40mg/m2 in this patient population. These results warrant further evaluation in previously treated lung cancer.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address